<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Target to Lead Selection for ADCs and Biologics

Journey through the drug discovery pipeline from target discovery to in vivo pharmacology. Take advantage of the Largest biobank of patient-derived models, Model development capabilities, Cell-based assays for Screening ADCs, and advanced downstream analysis.

Learn More

Immuno-oncology Targets & Combinations

Leverage comprehensive in vitro, in vivo, ex vivo, and in silico platforms, utilizing immunocompetent, humanized, or patient-derived models. With robust biomarker analysis and a focus on checkpoint inhibitors, you can optimize combination strategies.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Preclinical Consulting Services

Learn more about how our consulting services can help to support your journey to the clinic.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Crown Bioscience, Inc. Enters into Strategic Partnership with Jiangsu Hengrui Medicine Co., Ltd. for the Discovery and Commercialization of Novel Therapeutic Monoclonal Antibodies

CROWN BIOSCIENCE, INC., A LEADING GLOBAL DRUG DISCOVERY COMPANY, AND JIANGSU HENGRUI MEDICINE CO., LTD. (“HENGRUI”), A MAJOR CHINESE PHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT CROWNBIO TAICANG BIOLOGICS DIVISION, A WHOLLY OWNED SUBSIDIARY OF CROWN BIOSCIENCE, INC., AND HENGRUI HAVE ENTERED INTO A STRATEGIC PARTNERSHIP FOR THE DISCOVERY AND COMMERCIALIZATION OF A NOVEL THERAPEUTIC MONOCLONAL ANTIBODY (“MAB”) FOR THE CHINESE AND GLOBAL MARKET.

CrownBio and Hengrui have jointly evaluated multiple target opportunities and selected one that fits the two parties’ strategic interest and strength. With this partnership, Crown Biologics will lead the discovery program and deliver a humanized therapeutic antibody IND candidate. Hengrui will be responsible for further development and commercialization against major life threatening diseases in China and globally. CrownBio will receive research support and success-based incentive payment. “CrownBio is very pleased to establish its second long-term strategic partnership with a leading Chinese pharmaceutical company . This has certainly marked another milestone for CrownBio’s China initiative, which leverages our world class talent and drug discovery expertise in a focused disease area to advance innovative pharmaceutical products for patients.” Dr. Alex Wu, CEO of CrownBio, commented. “China’s bio-pharmaceutical market is entering an unprecedented growth era and poised to become the 2nd largest pharmaceutical market after the US. Our partnership with leading innovation driven pharmaceutical companies, such as Hengrui, demonstrates our commitment to bringing innovative medicines to patients.”

Dr. Lianshan Zhang, Hengrui’s President of Global R&D, added, “Hengrui is pleased to work with the talented team at CrownBio to accelerate our commitment to build a globally competitive therapeutic portfolio for Hengrui. We expect this partnership will bring two outstanding companies together and create a sustainable and successful long-term collaboration with win-win outcomes.”

 
ABOUT JIANGSU HENGRUI MEDICINE CO., LTD.

Jiangsu Hengrui Medicine Co., Ltd., established in 1970, is a fully integrated pharmaceutical company in China, with net sales of about US$550 million in 2010. The company has been experiencing organic growth at an annual rate of 25% in the past few years. It is recognized as the top innovative home-grown drug company, with over a dozen of new molecular entities in clinical trials and dozens more under pre-clinical development. Hengrui’s products and R&D span over multiple therapeutic areas, such as oncology, cardiovascular and metabolic diseases, CNS, inflammation, hematology and anesthesiology. For more information, please visit http://www.hrs.com.cn/.

 

ABOUT CROWN BIOSCIENCE, INC. 

Founded in 2006, Crown Bioscience is a premier drug discovery company providing cutting-edge translational platforms and cost effective drug discovery solutions for its biotech and pharmaceutical partners in dedicated therapeutic areas: Oncology and Metabolic Disease. Our proprietary HuPrime®, HuKemia®, HuBase ™, and HuMark ™, platforms enable unique lead optimization and translational strategies to deliver superior clinical candidates. Headquartered in Santa Clara California, Crown Bioscience has operations in China (Beijing and Jiangsu Taicang) and the USA (NC) with business offices in the Boston, Princeton, RTP, Phoenix, Milan and Shanghai. For more information, please visit http://www.crownbio.com.

Upcoming Events

EORTC-NCI-AACR Symposium 2024

October 23-25, 2024|Barcelona, Spain

Learn More

Biomarkers US 2024

October 28-29, 2024|San Diego, CA

Learn More